Association of Polymorphisms of Cytochrome P450 2D6 with Blood Hydroxychloroquine Levels in Patients with Systemic Lupus Erythematosus

Arthritis and Rheumatology

Volumn 68, Issue 1, 2016, Pages 184-190

  Lee, Ji Yeon ^a   Vinayagamoorthy, Nadimuthu ^a   Han, Kyungdo ^a   Kwok, Seung Ki ^a   Ju, Ji Hyeon ^a   Park, Kyung Su ^a   Jung, Seung Hyun ^a   Park, Sung Won ^a   Chung, Yeun Jun ^a,b   Park, Sung Hwan ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; N DESETHYL HYDROXYCHLOROQUINE; PREDNISOLONE; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; CYP3A4 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; DESETHYLHYDROXYCHLOROQUINE;

ADULT; ARTICLE; CROSS-SECTIONAL STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; GENETICS; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLISM;

ADULT; ANTIRHEUMATIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; FEMALE; GENE FREQUENCY; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84951941459     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39402     Document Type: Article

References (43)

1. Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991; 324: 150-4.
2. Kalia S, Dutz JP., New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther 2007; 20: 160-74.
3. Munster T, Gibbs JP, Shen D, Baethge BA, Botstein GR, Caldwell J, et al., Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum 2002; 46: 1460-9.
4. Costedoat-Chalumeau N, Amoura Z, Hulot JS, Hammoud HA, Aymard G, Cacoub P, et al., Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54: 3284-90.
5. Tett SE, Cutler DJ, Beck C, Day RO., Concentration-effect relationship of hydroxychloroquine in patients with rheumatoid arthritis: a prospective, dose ranging study. J Rheumatol 2000; 27: 1656-60.
6. Carmichael SJ, Charles B, Tett SE., Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. Ther Drug Monit 2003; 25: 671-81.
7. Furst DE., Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus 1996; 5 Suppl 1: S11-5.
8. Sailler L, Puissant B, Meliani P, Castex JO, Saivin S, Adoue D, et al., Blood concentrations of hydroxychloroquine and its desethyl derivative correlate negatively with the percentage of CD45RO+ cells among CD4+ lymphocytes in hydroxychloroquine-treated lupus patients. Ann N Y Acad Sci 2007; 1108: 41-50.
9. Frances C, Cosnes A, Duhaut P, Zahr N, Soutou B, Ingen-Housz-Oro S, et al., Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch Dermatol 2012; 148: 479-84.
10. Tanaka E, Taniguchi A, Urano W, Yamanaka H, Kamatani N., Pharmacogenetics of disease-modifying anti-rheumatic drugs. Best Pract Res Clin Rheumatol 2004; 18: 233-47.
11. Davila L, Ranganathan P., Pharmacogenetics: implications for therapy in rheumatic diseases. Nat Rev Rheumatol 2011; 7: 537-50.
12. Kim KA, Park JY, Lee JS, Lim S., Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. Arch Pharm Res 2003; 26: 631-7.
13. Projean D, Baune B, Farinotti R, Flinois JP, Beaune P, Taburet AM, et al., In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos 2003; 31: 748-54.
14. Lee SW, Lee M, Lee DD, Kim C, Kim YJ, Kim JY, et al., Biological resistance of hydroxychloroquine for Plasmodium vivax malaria in the Republic of Korea. Am J Trop Med Hyg 2009; 81: 600-4.
15. Wahie S, Daly AK, Cordell HJ, Goodfield MJ, Jones SK, Lovell CR, et al., Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: a retrospective cohort study. J Invest Dermatol 2011; 131: 1981-6.
16. Gil JP, Gil Berglund E., CYP2C8 and antimalaria drug efficacy. Pharmacogenomics 2007; 8: 187-98.
17. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M., Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994; 46: 452-9.
18. Fukuda T, Yamamoto I, Nishida Y, Zhou Q, Ohno M, Takada K, et al., Effect of the CYP2D6∗10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. Br J Clin Pharmacol 1999; 47: 450-3.
19. Lamba JK, Lin YS, Schuetz EG, Thummel KE., Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54: 1271-94.
20. Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O, et al., Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 2002; 30: 1108-14.
21. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, et al., Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 2002; 30: 883-91.
22. Diaz-Molina B, Tavira B, Lambert JL, Bernardo MJ, Alvarez V, Coto E., Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation. Transplant Proc 2012; 44: 2635-8.
23. Fukushima-Uesaka H, Saito Y, Watanabe H, Shiseki K, Saeki M, Nakamura T, et al., Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum Mutat 2004; 23: 100.
24. Lee SJ, Lee SS, Jung HJ, Kim HS, Park SJ, Yeo CW, et al., Discovery of novel functional variants and extensive evaluation of CYP2D6 genetic polymorphisms in Koreans. Drug Metab Dispos 2009; 37: 1464-70.
25. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A., Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002; 53: 111-22.
26. McGraw J, Waller D., Cytochrome P450 variations in different ethnic populations. Expert Opin Drug Metabol Toxicol 2012; 8: 371-82.
27. Kim YM, Yoo SH, Kang RY, Kim MJ, Bae YY, Lee YK, et al., Identifying drugs needing pharmacogenetic monitoring in a Korean hospital. Am J Health Syst Pharm 2007; 64: 166-75.
28. Yeo CW, Lee SJ, Lee SS, Bae SK, Kim EY, Shon JH, et al., Discovery of a novel allelic variant of CYP2C8, CYP2C811, in Asian populations and its clinical effect on the rosiglitazone disposition in vivo. Drug Metab Dispos 2011; 39: 711-6.
29. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al., The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
30. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
31. Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al., Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677-86.
32. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-40.
33. Wang LZ, Ong RY, Chin TM, Thuya WL, Wan SC, Wong AL, et al., Method development and validation for rapid quantification of hydroxychloroquine in human blood using liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2012; 61: 86-92.
34. Fuzery AK, Breaud AR, Emezienna N, Schools S, Clarke WA., A rapid and reliable method for the quantitation of hydroxychloroquine in serum using turbulent flow liquid chromatography-tandem mass spectrometry. Clin Chim Acta 2013; 421: 79-84.
35. Sachse C, Brockmoller J, Bauer S, Roots I., Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60: 284-95.
36. Hersberger M, Marti-Jaun J, Rentsch K, Hanseler E., Rapid detection of the CYP2D63, CYP2D64, and CYP2D66 alleles by tetra-primer PCR and of the CYP2D6∗5 allele by multiplex long PCR. Clin Chem 2000; 46: 1072-7.
37. Heim MH, Meyer UA., Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. Genomics 1992; 14: 49-58.
38. Kubota T, Yamaura Y, Ohkawa N, Hara H, Chiba K., Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol 2000; 50: 31-4.
39. Cholerton S, Daly AK, Idle JR., The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci 1992; 13: 434-9.
40. Cho JH, Yoon YD, Park JY, Song EJ, Choi JY, Yoon SH, et al., Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients. Transplant Proc 2012; 44: 109-14.
41. Carmichael SJ, Day RO, Tett SE., A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus. Intern Med J 2013; 43: 547-53.
42. Tett SE, Cutler DJ, Day RO., Bioavailability of hydroxychloroquine tablets assessed with deconvolution techniques. J Pharm Sci 1992; 81: 155-9.
43. Lee J, Luc S, Greenblatt D, Kalish R, McAlindon T., Factors associated with blood hydroxychloroquine level in lupus patients: renal function could be important. Lupus 2013; 22: 541-2.